Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
25,279
Total Claims
$4.3M
Drug Cost
1,058
Beneficiaries
$4,109
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+191%
Cost per patient vs peers
$4,109 vs $1,411 avg
+79%
Brand preference vs peers
19.0% vs 10.6% avg
Brand vs Generic
Brand: 4,677 claims · $3.8M
Generic: 19,952 claims · $510K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 941 | $940K |
| Lipase/Protease/Amylase | 427 | $553K |
| Icosapent Ethyl | 808 | $464K |
| Diclofenac Epolamine | 481 | $345K |
| Sitagliptin Phosphate | 172 | $161K |
| Denosumab | 78 | $136K |
| Icosapent Ethyl | 373 | $132K |
| Tenofovir Alafenamide | 88 | $130K |
| Dulaglutide | 86 | $108K |
| Semaglutide | 67 | $96K |
| Apixaban | 82 | $77K |
| Mirabegron | 85 | $67K |
| Lipase/Protease/Amylase | 33 | $56K |
| Insulin Glargine,hum.Rec.Anlog | 116 | $53K |
| Linagliptin | 55 | $50K |
Prescribing Profile
Patient Profile
74
Avg Age
53%
Female
1.07
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data